Molecular study of Recent Virus and its relationship to Pityriasis rosea
Main Article Content
Keywords
(PR), COVID-19, PCR
Abstract
Background: A new type of coronavirus family (SARS-CoV-2), that has been detected in individuals with several clinical symptoms named (COVID-19), was recognized as a pandemic on March 11, 2020. Numerous researches have been conducted on manifestations of skin disease related to COVID-19, i.e. rashes, pityriasis rosea (PR), vascular markings, and lesions as pimple-like.
Aim: This study aims to find out if the Coronavirus can affect (PR) development which also can be considered as a trigger and symptom for other types of infections.
Material and Methods: A case series descripting the dermatological finding of COVID-19 in Thi-Qar Governorate, a collective sample taking from inpatients, outpatients, the emergency unit of Al Hussein Teaching Hospital, and inwards of Al-Shefaa' Isolation Hospital. The study has been done over a four-month period (June-September, 2020.)
Results: 19 patients (10 females and 9 males), who have infected with Coronavirus and were suffering from (PR), are included in this study. The highest percentage of females 52.6% and males 47.4%. The distribution of patients according to the incidence of (PR) in typical and anomalous manners had the percentage of typical 77.9% and abnormal 21.1%. The highest percentage was in moderate Covid-19 (84.2%), while it was 15.8% in mild Covid-19. There was no significant statistical difference in mean age distribution according to gender while there were significant statistical differences according to (PR) and COVID-19 class. More studies are needed to evaluate whether or not these lesions are associated with the virus.
Conclusion: The (PR) was one of the dermatological finding of COVID-19, that did not have a clear role in the distribution of the disease according to the background of the patients and also the severity of COVID-19. It can be triggered by COVID-19 and completely cured with the clearance of the disease.
Recommendation: An accurate robust cutaneous documentation related to Covid19 is required to increase the knowledge of disease as well as its epidemiology.
References
[2] C. G. Casas et al., “Classification of the cutaneous manifestations of COVID-19 : a rapid prospective nationwide consensus study in Spain with 375 cases,” Br. J. Dermatol., vol. 183, no. 6, pp. 71–77, 2020.
[3] I. Torres-Navarro, C. Abril-Perez, J. Roca-Gines, J. Sanchez-Arraez, and R. Botella-Estrada, “Erythema multiforme and Kawasaki disease associated with COVID-19 infection in children,” Eur. Acad. Dermatology Venereol., vol. 34, no. 6, pp. 539–541, 2020.
[4] K. Mahajan, V. Relhan, A. K. Relhan, and V. K. Garg, “(PR) : An Update on Etiopathogenesis and Management of Difficult Aspects,” Indian J. Dermatol., vol. 61, no. 4, pp. 375–384, 2016.
[5] A. A. T. Chuh and V. Zawar, “(PR) ,” Harper’s Textb. Pediatr. Dermatology, vol. 34, no. 6, pp. 416–421, 2020.
[6] V. Zawar, H. Jerajani, and R. Pol, “Current trends in (PR) ,” Expert Rev. Dermatol, vol. 5, no. 3, pp. 325–333, 2010.
[7] R. Balestri, G. Rech, and C. R. Girardelli, “(PR) as a cutaneous manifestation of COVID-19 infection,” Eur. Acad. Dermatology Venereol., vol. 34, no. 7, pp. 436–437, 2020.
[8] U. Wollina, A. S. Karada!, and C. Rowland-Payne, “Cutaneous signs in COVID-19 patients : A review,” Dermatol. Ther., vol. 6, no. 5, pp. 1–6, 2020.
[9] G. Stinco, M. Ruscio, D. Proscia, and F. Piccirillo, “Borrelia Infection and (PR) ,” Acta Derm Venereol, vol. 89, no. 6, pp. 97–98, 2008.
[10] S. A. Temiz et al., “Evaluation Of DermatologyConsultationsInTheEra Of COVID19,” Orig. Artic., vol. 6, no. 7, pp. 1–10, 2020.
[11] M. YUKSEL, “(PR) Recurrence is Much Higher than Previously Known :A Prospective Study,” Investig. Rep., vol. 99, no. 9, pp. 664–667, 2019.
[12] S. T. S. Hassan, “Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19,” Viruses 2020, vol. 476, no. 12, pp. 12–15, 2020.
[13] C. S. Gonçalves et al., “Erythematous Papular Rash: A Dermatological Feature of COVID-19 Catarina,” Eur. J. Case Reports Intern. Med., vol. 5, no. 5, pp. 56–58, 2020.
[14] D. M. Enguix, M. del C. S. Nievas, and D. T. M. Romeroc, “(PR) Gibert type rash in an asymptomatic patient that tested positive for COVID-19,” vol. 155, no. 6, p. 273, 2020.
[15] P. Suchonwanit, “Diagnostic and prognostic values of cutaneous manifestations in COVID-19,” Dermatologic Therapy, no. 5. pp. 10–11, 2020.
[16] Ö. Kutlu and A. Metin, “Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of the COVID-19 pandemic,” Dermatol. Ther., vol. 8, no. 7, pp. 1–5, 2020.
[17] G. Daneshgaran, D. P. Dubin, and D. J. Gould, “Cutaneous Manifestations of COVID ‑ 19 : An Evidence ‑ Based Review,” Am. J. Clin. Dermatol., vol. 21, no. 5, pp. 627–639, 2020.
[18] A. Català et al., “Maculopapular eruptions associated to COVID-19 : A subanalysis of the COVID-Piel study,” Dermatologic Ther., vol. 26, no. 6, pp. 1–10, 2020.
[19] S. Shaukat, G. Butt, and I. Hussain, “Cutaneous manifestations of COVID-19,” J. Pakistan Assoc. Dermatologists, vol. 30, no. 1, pp. 181–189, 2020.
[20] S. L. Mawhirt, D. Frankel, and A. M. Diaz, “Cutaneous Manifestations in Adult Patients with COVID-19 and Dermatologic Conditions Related to the COVID-19 Pandemic in Health Care Workers,” Curr. Allergy Asthma Rep., vol. 12, no. 10, pp. 1–13, 2020.
[21] Ç. Turan, N. Metin, Ö. S. Kotan, UtlumZeynep, and Ö. Ümran, “Change of the diagnostic distribution in applicants to dermatology after COVID-19 pandemic : What it whispers to us ?,” Dermatol. Ther., vol. 4, no. 6, pp. 1–9, 2020.
[22] Tahmasebi, Safa, et al. "The effects of oxygen–ozone therapy on regulatory T‐cell responses in multiple sclerosis patients." Cell biology international (2021).
[23] D. Lipsker, “Paraviral eruptions in the era of COVID-19 : Do some skin manifestations point to a natural resistance to SARS-CoV-2 ?,” Clin. Dermatol., vol. 6, no. 7, pp. 1–5, 2020.
[24] Shabgah, Arezoo Gowhari, et al. "CXC chemokine ligand 16: a Swiss army knife chemokine in cancer." Expert Reviews in Molecular Medicine 23 (2021).
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.